Table 4– Predicted number of deaths and drug resistance among deaths after standardised initial treatment followed by standardised retreatment (hypothetical cohorts of 1,000 new cases in each country start initial therapy with one of two standardised regimens)
CountryInitial regimenDeaths during initial and retreatment nDrug resistance pattern among those who died during initial and retreatment
Pan-sensitiveAny resistance (except MDR)MDR
Dominican Republic2HRZE/6HE125341255
2HRZE/4HR12033858
Peru2HRZE/6HE8960733
2HRZE/4HR8559535
Vietnam2HRZE/6HE85492821
2HRZE/4HR73552222
UR Tanzania2HRZE/6HE678767
2HRZE/4HR648639
Nicaragua2HRZE/6HE678497
2HRZE/4HR638469
Gambia2HRZE/6HE668938
2HRZE/4HR638928
Kenya2HRZE/6HE6390100
2HRZE/4HR599271
  • Data are presented as % and rounded to whole numbers, unless otherwise stated. MDR: multidrug-resistance; 2HRZE: isoniazid, rifampin, pyrazinamide and ethambutol for 2 months; 6HE: isoniazid plus ethambutol for 6 months; 4HR: isoniazid plus rifampin for 4 months.